RxDoctor Payments Data

Karen Tang

Family · Folsom, CANPI 1013493279

Payments from drug & device makers

$2,147in general payments, 2019–2025

Across 97 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$285
  • Novo Nordisk$270
  • Pfizer$256
  • Lilly USA, LLC$213
  • AbbVie$203
  • GSK$186
  • plus $734 from 19 others

What the payments were for

  • Food & beverage$2,147100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,147 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$29,057
OzempicSemaglutide22$20,631
MounjaroTirzepatide12$13,562
Breo ElliptaFluticasone/Vilanterol13$6,091
Metformin Er OsmoticMetformin Hcl11$2,431
Albuterol Sulfate HfaAlbuterol Sulfate45$2,009
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,489
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$864
Levothyroxine Sodium35$817
Ketoconazole14$656
Gabapentin53$637
Pantoprazole Sodium21$600
Atorvastatin Calcium83$582
Hydroxyzine Hcl20$463
Losartan Potassium57$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$29,05720 claims
Novo NordiskOzempic$270$20,63122 claims
Lilly USA, LLCMounjaro$213$13,56212 claims
GSKBreo Ellipta$186$6,09113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →